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Abstract Notwithstanding the success of the traditional
dietary phenylalanine restriction treatment in phenylketon-
uria (PKU), the use of large neutral amino acid (LNAA)
supplementation rather than phenylalanine restriction has
been suggested. This treatment modality deserves attention
as it might improve cognitive outcome and quality of life in
patients with PKU. Following various theories about the
pathogenesis of cognitive dysfunction in PKU, LNAA
supplementation may have multiple treatment targets: a
specific reduction in brain phenylalanine concentrations, a
reduction in blood (and consequently brain) phenylalanine
concentrations, an increase in brain neurotransmitter con-
centrations, and an increase in brain essential amino acid
concentrations. These treatment targets imply different
treatment regimes. This review summarizes the treatment
targets and the treatment regimens of LNAA supplementa-
tion and discusses the differences in LNAA intake between
the classical dietary phenylalanine-restricted diet and
several LNAA treatment forms.
Abbreviations
CSF Cerebrospinal fluid
LNAA Large neutral amino acids
PAH Phenylalanine hydroxylase
Phe Phenylalanine
PKU Phenylketonuria
Introduction
In phenylketonuria (PKU, OMIM 261600), dietary restric-
tion of phenylalanine (Phe) has been the cornerstone of
treatment for over 50 years. The result of dietary treatment
is a near normal cognitive outcome, although mild
neuropsychological disturbances may still occur (Christ et
al. 2010). Large neutral amino acids (LNAAs) have been
suggested as an alternative treatment to further improve
outcome. Possible LNAA treatment targets include reduc-
tion of brain Phe concentrations (Berry et al. 1982; Jordan
et al. 1985; Pietz et al. 1999), reduction of blood Phe
concentrations (Matalon et al. 2006), augmentation of
cerebral neurotransmitter synthesis (Lou et al. 1985; Güttler
and Lou 1986; Lou et al. 1987; Lykkelund et al. 1988), and/
or elevation of brain non-Phe LNAA concentrations (Van
Spronsen et al. 2009). In this article, we summarize the
reports of the clinical trials of LNAAs and the rationales
behind the use of LNAAs.
Apart from Phe, LNAAs include tyrosine, tryptophan,
threonine, methionine, valine, isoleucine, leucine, and
histidine (Van Spronsen et al. 2009). In healthy individuals,
all of these except tyrosine are essential amino acids. In
patients with PKU, tyrosine has become an essential amino
acid. LNAA treatment as an alternative to dietary Phe
restriction was suggested as early as 1948 (Christensen et
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DOI 10.1007/s10545-010-9216-1al. 1948) and first studied in rats in 1976 (Andersen and
Avins 1976). Since then, different combinations of LNAAs
have been designed, based on different rationales and
treatment targets. Some LNAA combinations contain
arginine and/or lysine, neither of which is an LNAA.
This paper reviews different treatment regimes and
different treatment rationales in LNAA supplementation.
Rationale A: LNAA supplementation to decrease
cerebral Phe concentrations
The underlying rationale for this therapeutic strategy is
that elevated brain Phe concentrations are considered to
be neurotoxic. Because all LNAAs share a common
transport system in order to enter the brain, and high
plasma concentrations of LNAAs may block the
transport of Phe into the brain (Pardridge 1998),
increasing blood LNAA concentrations may reduce
uptake of Phe into the brain. This hypothesis was first
studied in rats with experimental hyperphenylalaninemia.
LNAA-treated hyperphenylalaninemic rats were shown
to have significantly reduced brain Phe concentrations
compared to untreated hyperphenylalaninemic control
rats, at similar blood Phe concentrations (Andersen and
Avins 1976). Later studies in PKU patients showed that
supplementation with valine, isoleucine, and leucine
resulted in slightly improved neuropsychological func-
tion in patients with PKU (Jordan et al. 1985; Berry et al.
1990). More recent studies included the administration of
all LNAAs. Pietz et al. (1999)a n dM o a t se ta l .( 2003)
showed that oral LNAA supplementation reduced brain
Phe concentrations, and improved neurophysiological
and neuropsychological functioning (Pietz et al. 1999;
Moats et al. 2003; Schindeler et al. 2007). Differences in
outcome may be related to composition, dosing, route of
administration, and duration of the supplementation
period.
Rationale B: tyrosine and/or tryptophan
supplementation to increase cerebral neurotransmitter
synthesis
The rationale for this therapeutic strategy is that high plasma
Phe concentrations result in decreased brain neurotransmitter
concentrations. This is reflected by reduced brain neurotrans-
mitter concentrations in the PKU mouse brain (Puglisi-Allegra
et al. 2000;P a s c u c c ie ta l .2002, 2008, 2009) ,a n db yr e d u c e d
concentrations of dopamine and serotonin and their metabo-
l i t e si nP K Up a t i e n t s ,b o t hi nc e r e b r o s p i n a lf l u i d( C S F )
(Butler et al. 1981; Lou et al. 1985; Burlina et al. 2000), and
in autopsied brain tissue (McKean 1972). In PKU patients
with an unrestricted natural protein intake, tyrosine and
tryptophan supplementation have been shown to improve
neurotransmitter metabolism, reaction time, and vigilance
(Güttler and Lou 1986; Lou et al. 1987; Lykkelund et al.
1988), suggesting that dietary treatment could be replaced by
a combination of tyrosine and tryptophan. Further support for
such a treatment strategy was based on the theory of prefrontal
lobe dysfunction (Diamond et al. 1994). This theory presumes
that the prefrontal cortex is most affected by dopamine
depletion, because dopaminergic neurons innervating the
prefrontal cortex have relatively high levels of activity and
higher dopamine turnover, inducing dopamine-dependency.
Following these lines of consideration, large doses of
tyrosine or L-dopa were expected to have a positive effect.
However, later studies with large doses of tyrosine or L-
dopa did not show positive results (Lou 1994; Mazzocco et
al. 1992;P i e t ze ta l .1995; Smith et al. 1998; Ullrich et al.
1996).
Rationale C: LNAA supplementation to decrease blood
Phe concentrations
Thistherapeutic strategyofsupplementing LNAAisbased on
the rationale that LNAA transport not only occurs at the
blood–brain barrier (BBB), but also at the gut–blood barrier.
After performing studies in mice, Matalon et al. (2003)
performed an open and a double-blinded trial in patients,
who received LNAAs three times daily with meals, while
patients’ regular diet was unchanged (Matalon et al. 2006,
2007). A decrease in blood Phe concentrations up to 50% of
initial values was found on LNAA supplementation of 0.5–
1 . 0gk g
−1 day
−1 (Matalon et al. 2006, 2007). This suggests
that LNAA supplementation superimposed on regular
dietary treatment may reduce Phe absorption in the gastro-
intestinal tract. If reduction in blood Phe concentrations
indeed results from reduced Phe absorption, supplementation
of all LNAAs at this dosage may not be required, as
supplementation with threonine up to 50 mg/kg is reported
to be sufficient to reduce blood Phe concentration by 20–
50% (Sanjurjo et al. 2003). In addition, the reduction of
blood Phe concentrations following LNAA supplementa-
tion may at least partly resultf r o mi n c r e a s e dp r o t e i n
synthesis resulting from increased essential amino acid
availability, in case of essential amino acid deficiency.
However, it is largely unknown whether the patients
studied had essential amino acid deficiencies (due to
insufficient intake of natural protein and/or protein
substitute), as so far, none of the clinical studies on the
effects of LNAA supplementation quantified the amount
of natural protein and protein substitute intake patients
used. Finally, reduced blood Phe concentrations on
LNAA supplementation may just be a matter of timing
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(personal communication).
Rationale D: LNAA supplementation to increase
cerebral amino acid concentrations
Reduced brain LNAA concentrations have been reported in
PKU mice (Smith and Kang 2000; Pascucci et al. 2002,
2008). In autopsied brain tissue of PKU patients, McKean
reported reduced tyrosine concentrations (McKean 1972).
Restoring reduced brain LNAA concentrations in PKU may
improve cognitive outcome. The rationale for LNAA
supplementation to increase cerebral LNAA concentrations
is, again, that LNAAs share the same transport system as
Phe for entering the brain. Where rationale A hypothesizes
that it is important to decrease the brain Phe concentration,
rationale D hypothesizes that a deficiency in any essential
amino acid in the brain may affect brain (protein)
metabolism. Consequently, rationale D focuses on the
effect of LNAA treatment on brain LNAA concentrations,
rather than on (a decrease in) brain Phe concentrations.
Hoeksma et al. (2009) showed that a significant negative
relationship exists between plasma Phe concentration and
cerebral protein synthesis in patients with PKU. However,
this finding does not differentiate between the influence of
elevated brain Phe concentrations and reduced brain non-
Phe LNAA concentrations on cerebral protein synthesis.
Rationale E: comparison of LNAA intake in LNAA
treatment and present dietary treatment
Recent trials with LNAA supplements in PKU patients
include LNAA alone (Pietz et al. 1999), LNAA with extra
lysine and/or arginine (Koch et al. 2003; Moats et al. 2003;
Matalon et al. 2006, 2007; Schindeler et al. 2007), or only
threonine (Sanjurjo et al. 2003). Whatever combination of
amino acids is given, LNAA treatment strategies start with a
more or less normal (i.e., unrestricted) intake of natural
protein. The response of blood Phe concentrations to LNAA
treatment (Pietz et al. 1999;K o c he ta l .2003; Moats et al.
2003; Matalon et al. 2006, 2007; Schindeler et al. 2007)i s
comparable to the response of blood Phe concentrations to
the protein substitutes in the traditional dietary treatment
(MacDonald et al. 1996; Crone et al. 2005).
To illustrate treatment-dependent differences in LNAA
intake, we calculated prescribed LNAA intake for several
treatment regimes, based onan adult PKU patient witha body
weightof70kg(Fig.1). In Fig. 1, prescribed LNAA intake is
compared among four different diets: (1) conventional
dietary PKU treatment consisting of Phe-restriction com-
bined with synthetic amino acid mixtures, (2) LNAA
supplementation (0.5 g kg
−1 day
−1) with natural protein
intake at 0.8 g kg
−1 day
−1, the recommended daily allowance
(RDA) (National Research Council 1989), (3) LNAA
supplementation combined with conventional dietary treat-
ment, (4) RDA of protein of healthy adults. For calculation
of LNAA content of synthetic amino acid mixtures
(treatment 1), the mean of the following 14 amino acid
mixtures was used: PKU3® (Milupa), PKU3advanta®
(Milupa), XP Maxamum® (SHS), Lowphlex Powder®
(SHS), Phlexy-10 drinkmix® (SHS), Phlexy-10 tablets®
(SHS), PK Aid-4® (SHS), Aminogran® (UCB Pharma),
PKU Express Powder® (Vitaflo), Phenex-2® (Ross), Xphe
advance® (Metax), Easiphen® (SHS), PKU Express Liquid®
(Vitaflo), Lophlex Liquid® (SHS). Regarding LNAA sup-
plementation (treatments 2 and 3), a dose of 0.5 g kg
−1 day
−1
is used, based on several recent trials following the work of
Moats et al. (2003) and Koch et al. (2003). Prescribed
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of Lanaflex® (SHS international) and NeoPhe® (Solace
Nutrition). The dietary regimen of LNAA supplementation
combined with conventional dietary treatment (treatment 3)
reflects the regimen studied by Matalon et al. (2006, 2007).
Several assumptions underlie the calculated values. First,
the dose of amino acid mixture in conventional treatment is
set at 1.0 g kg
−1 day
−1 rather than the RDA (0.8 g kg
−1
day
−1), correcting for the assumed 20% of the mixture that
is not absorbed in the gastrointestinal tract. Second, in
conventional treatment, LNAA intake resulting from
natural protein intake is not taken into account, as the
natural protein in this treatment is assumed to be of
relatively low nutritional value. However, the distinction
between protein of relatively low and high nutritional value
has not been applied to the prescribed LNAA intake at
RDA of healthy controls, resulting in some inconsistencies.
Based on these calculated prescribed LNAA intakes,
Fig. 1 demonstrates that LNAA intake in PKU is higher
than in healthy controls, regardless of the specific treatment
given. Moreover, LNAA intake on LNAA supplementation
is higher than LNAA intake on conventional treatment.
However, the difference in LNAA intake between these two
treatment forms is small relative to the difference between
conventional treatment and the dietary regimen studied by
Matalon et al. Finally, LNAA intake on the treatment
strategy studied by Matalon et al. clearly results in a higher
LNAA intake than either conventional therapy or LNAA
supplementation, and markedly exceeds LNAA intake of a
healthy control.
When LNAA treatment is discussed, not only the dose
but also the composition is important. It is remarkable that
LNAA treatment would need the addition of the non-
LNAA lysine and arginine. When the primary aim is to
block the entrance of Phe into brain, this would favor
LNAA supplements consisting of specific amino acids,
such as leucine, isoleucine, and methionine, that are
considered to be highly effective at decreasing the cerebral
Phe concentration (Hargreaves and Pardridge 1998). Fol-
lowing that hypothesis, giving 0.5 g kg
−1 day
−1 of all
LNAA together with lysine and arginine might be changed
i n t o0 . 5gk g
−1 day
−1 of leucine, isoleucine, and/or
methionine (Hargreaves and Pardridge 1998).
When the primary aim is to increase the influx of
tyrosine and tryptophan, this would favor the supplemen-
tation of only tyrosine and tryptophan to increase the
synthesis of the neurotransmitters dopamine and serotonin
in the brain. Following that hypothesis, giving 0.5 g kg
−1
day
−1 of all LNAA (with or without lysine and/or arginine)
might be changed into 0.5 g kg
−1 day
−1 of tyrosine and
tryptophan. This is clearly above the doses ever given to
PKU patients so far (Lou et al. 1985, 1987; Güttler and Lou
1986; Lykkelund et al. 1988). When, however, increasing
the cerebral concentrations of all essential amino acids is
the primary aim, all essential amino acids should be given
in such a way that normal concentrations of all essential
amino acids are achieved, taking the Km of each amino acid
into account.
Summary of current treatment strategies in LNAA
supplementation
LNAA supplementation may have several treatment aims:
reducing brain Phe concentrations, reducing plasma Phe
concentrations, increasing cerebral neurotransmitter con-
centrations, and increasing cerebral essential amino acid
concentrations. Although LNAA treatment in PKU was
initially intended to be unrestricted natural protein intake
combined with LNAA supplementation, it should be noted
that not all authors studied LNAA supplementation in this
manner. This deserves attention when interpreting the
findings below.
First, LNAA supplementation has been found to reduce
brain Phe concentrations in patients, even at mean plasma
Phe concentrations >1,000 μmol/L (Pietz et al. 1999; Koch
et al. 2003). Second, LNAA supplementation may reduce
plasma Phe concentrations (Matalon et al. 2006, 2007;
Sanjurjo et al. 2003), although not all authors report this
effect (Pietz et al. 1999; Koch et al. 2003; Moats et al.
2003). Third, data suggest that supplementation with only
tyrosine and tryptophan does not sufficiently correct
biochemical and neuropsychological abnormalities. How-
ever, recent LNAA trials supplement LNAA at 0.5 g kg
−1
day
−1, a dose much higher than that studied for tyrosine and
tryptophan supplementation. At this dose, the effect of
LNAA supplementation on cerebral neurotransmitter con-
centrations is currently unknown. Fourth, LNAA supple-
mentation combined with unrestricted natural protein intake
has been suggested to increase cerebral essential amino acid
concentrations. This hypothesis remains to be studied in
future trials.
In conclusion, LNAA treatment is seen as an alternative
to conventional dietary PKU treatment. Although usually
considered to refer to a single specific treatment modality,
this paper shows that LNAA treatment may refer to at least
two different LNAA treatment strategies, i.e., natural
protein intake at RDA with LNAA supplementation, and
conventional dietary therapy combined with LNAA sup-
plementation. In addition, LNAA treatment may refer to
supplementation of single amino acids, such as tyrosine,
tryptophan, and threonine. These differences in treatment
strategies are based on clearly different theories regarding
mechanism of action. Consequently, more in-depth studies
are necessary to investigate the potential role, dose, and
composition of LNAA in PKU treatment.
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